Articles tagged with Glioblastomas
Researchers identified ELTD1 as a promising biomarker for diagnosing gliomas, particularly high-grade glioblastoma multiforme (GBM). Studies found that ELTD1 levels were strongly associated with glioma development and prognosis.
Researchers identified a fusion between FGFR3 and TACC3 genes in human glioblastoma samples, which promoted tumor growth and progression in a mouse model. The fusion protein escaped regulation by miR-99a, indicating its potential as a prognostic marker and drug target for glioblastoma treatment.
Researchers found a small peptide that blocks antibody recognition of desmogleins, improving cell-cell adhesion and preventing skin blistering in pemphigus vulgaris. Additionally, spironolactone reduced vascular calcification in kidney disease mice, increasing their life span. A glioblastoma fusion gene promoted tumor growth and progre...
Research demonstrates that immune system's natural killer cells can kill off virus-infected tumor cells, rendering glioblastoma virotherapy less effective. The study suggests temporarily suppressing the immune system may counteract this response and enhance therapy.
A team of researchers at MD Anderson Cancer Center has identified a cancer-promoting protein's pathway into the cell nucleus and discovered how it fuels brain tumor growth. By targeting this pathway, they hope to develop new treatments for glioblastoma multiforme, the most common and lethal form of brain cancer.
A novel blood test detects and monitors brain cancer biomarkers using nanotechnology and NMR technology, offering a promising diagnostic tool for glioblastoma multiforme patients. The study demonstrates excellent detection accuracy and potential for quick results from small blood samples.
A recent Johns Hopkins study found that repeated surgeries to remove glioblastomas, the most aggressive brain tumors, can increase median survival time from 14 months to 26.6 months. This may be due to increased efficacy of radiation and chemotherapy with each successive surgery.
Researchers at the Salk Institute have discovered that glioblastoma multiforme (GBM) can originate from cortical neurons, challenging previous assumptions about its origins. This finding suggests potential new targets to treat these deadly brain tumors and may help slow progression and recurrence.
Researchers at Cedars-Sinai Medical Center found that multifocal glioblastoma patients have significantly shorter overall survival compared to those with single tumors, even when treated with the same therapies. Median overall survival for multifocal patients was six months, while single-tumor patients survived 11 months.
Researchers at UT MD Anderson Cancer Center show how PKM2 contributes to brain tumor formation and growth by influencing histone proteins. Higher levels of PKM2 expression and H3 phosphorylation are correlated with shorter survival and higher grade tumors.
A recent study published in the Proceedings of the National Academy of Sciences reveals that a modification of the tumor suppressor gene PTEN is associated with resistance to glioblastoma treatments. The research suggests that targeting PTEN modification could lead to improved treatment outcomes for patients with glioblastoma.
A study at Columbia University Irving Medical Center found that a specific gene fusion is responsible for the majority of glioblastomas, leading to dramatic slowing of tumor growth in mice. The discovery opens up new possibilities for personalized treatments using FGFR kinase inhibitors.
TGen researchers will identify genetic differences in glioblastoma patients using whole genome sequencing, with the goal of developing personalized clinical trials. The foundation's funding supports two five-year projects aimed at extending patient survival and improving treatment outcomes.
Researchers discovered that bevacizumab can lead to invasive tumors in brain cancer patients, but found a new treatment strategy by targeting both VEGF and MET. This approach may improve survival rates for drug-resistant patients, offering hope for a more effective treatment.
Researchers have discovered a new method to sub-typing GBM tumor lines using proteins expressed, which could lead to targeted drug treatments and more accurate patient prognoses. The study found that patients with the CNP subtype may live up to 10 years after diagnosis.
Researchers at UW-Madison develop combination therapy that knocks out signaling of multiple EGFR family members in brain-cancer cells, inhibiting growth and evasion of current therapies. The study's lead author reports success with lapatinib treatment, a novel drug approved by the FDA.
Researchers at Fred Hutchinson Cancer Center have successfully transplanted gene-modified blood stem cells into brain cancer patients to protect their bone marrow against chemotherapy's toxic effects. The study showed that two patients survived longer than predicted, with one remaining alive for over three years.
A new brain cancer vaccine tailored to individual patients has proven effective in a multicenter phase 2 clinical trial, extending their lives by several months. The vaccine combined with the drug Avastin showed promise in treating recurrent glioblastoma multiforme, a type of brain cancer that kills thousands of Americans every year.
Glioblastoma is an incurable disease with a one-year survival rate. Researchers at the Feinstein Institute are presenting new data on potential treatments, including pharmacological inhibition of microglia and PDZ-RhoGEF.
Researchers have identified protein biomarkers that can help determine which GBM patients may benefit from standard treatment, enabling personalized medicine. A 'systems' approach also found networks of genes that characterize short-term survivors from long-term GBM survivors.
A study published in the Journal of Experimental Medicine found that persistent protein expression may explain why brain tumors return after therapy. The research suggests blocking an active VEGF receptor could represent a new treatment option for glioblastoma cases where traditional therapies have failed.
Researchers found that Toca 511 eliminates tumors in most animals after dosing with 5-FC, providing a dramatic survival benefit. The treatment was well-tolerated and did not cause toxicity over the six-month protocol.
A team of researchers has identified a potential new therapeutic target for the treatment of glioblastoma multiforme (GBM), a highly aggressive form of brain cancer. They found that protein SULF2 is expressed in primary human GBM tumors and cell lines, and its expression is associated with abnormal activation of signaling pathways down...
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor resistant to current therapies. Researchers at the University of California, San Francisco, have identified PDGFR-alpha and SULF2 as potential therapeutic targets for GBM treatment. Knocking down SULF2 expression decreased cell growth in human GBM cell lines.
Researchers identified genetic alterations affecting proteins known as histones in 48 pediatric glioblastomas, with 36% of cases featuring histone mutations. These mutations, which occur rarely in adult glioblastoma, may hold key to developing new treatments for the most malignant type of brain tumor.
Researchers have identified a new pathway that targets the root cause of glioblastoma resistance, paving the way for more effective treatments. By understanding how this complex signaling process works, scientists hope to develop novel therapies to improve patient outcomes and extend survival rates.
A University of Illinois study found that personalized prognostic tools and gene-based therapies can improve the survival and quality of life of glioblastoma patients. The researchers discovered new general and clinical-dependent gene profiles that can be used to predict patient outcomes and select targeted therapies.
A new study uses weather forecasting models to predict the spread of brain tumors, demonstrating the feasibility of a mathematical approach. The model, known as LETKF, provides accurate and efficient predictions of tumor growth and spread, taking into account errors in model parameters and measurement uncertainties.
Researchers identified a key protein mutation that enables brain tumors to invade healthy brain tissue. Excessive epidermal growth factor receptor (EGFR) signals trigger the production of GBP1, rendering tumors more invasive and allowing them to spread into surrounding tissue.
A team of researchers identified APNG as a contributor to GBM resistance to temozolomide, with high nuclear expression correlating to poorer survival. Monitoring APNG levels may provide insight into patient response to temozolomide treatment.
Four US clinical centers have begun providing access to Novocure's Tumor Treating Fields (TTFields) device for treating recurrent GBM, a deadly brain tumor. The device has shown clinical efficacy comparable to active chemotherapies with better quality of life.
A Massachusetts General Hospital study found that about 5% of glioblastomas contain extra copies of two or three key genes, which may explain the limited success of targeted therapies. The research team identified mosaic subpopulations of cells within tumors, each with its own unique genetic mutations and functions.
Scientists identified a novel gene mutation causing glioblastoma, a common type of malignant brain tumor. Two existing drugs targeting this mutation effectively prolonged the survival of mice, offering new hope for patients.
A study by Bo Hu and Shi-Yuan Cheng found that PDGFR-alpha overexpression in glioblastomas triggers a signaling cascade promoting tumor growth and invasion. Manipulating Dock180 to block this pathway inhibits PDGFR-alpha's role in glioma tumorigenesis.
Researchers discovered a molecular pathway driven by PDGFR-alpha that promotes the aggressive nature of a significant proportion of glioblastomas. Overexpressed in GBMs, this pathway triggers signaling cascades leading to tumor growth and invasion. Manipulating Dock180 phosphorylation disrupts this pathway, resulting in failed tumor pr...
Researchers are investigating a novel gene therapy approach using LG631 to improve tolerance and effectiveness of chemotherapy for glioblastoma, a devastating brain cancer. The study aims to prevent damage to bone marrow, enabling patients to receive higher doses with fewer side effects.
Researchers at VCU Massey Cancer Center have discovered a mechanism by which glioblastoma multiforme promotes neurodegeneration, leading to neuron death. AEG-1, an oncogene overexpressed in brain tumors, inhibits expression of EEAT2, a glutamate transporter, resulting in excitoxicity and excessive glutamate levels.
A study published in Cancer Cell reveals that the coupling of proteins FoxM1 and beta-catenin promotes glioblastoma development. The researchers found that this protein connection supports the self-renewal and differentiation of glioma-initiating cells, cancer stem cells thought to drive glioblastoma multiforme.
Scientists at Sanford-Burnham and Salk Institute developed a method to combine peptides and nanoparticles to eliminate glioblastoma in previously untreatable mouse models. The nanosystem proved effective in treating two different mouse models, curing most tumors and significantly delaying tumor development.
Researchers found that glioblastoma cells need large amounts of cholesterol to grow and survive. Cholesterol-manipulating drugs could potentially lead to significant tumor cell death if this laboratory work is confirmed in larger studies.
Researchers discovered that glioblastoma cells depend on large amounts of cholesterol for growth and survival, and that pharmacologically depriving them of cholesterol leads to death. This new strategy may lead to significantly more effective treatments for patients with this lethal form of brain cancer.
A novel gene therapy approach combining with radiation therapy has been found to be safe and effective in treating glioblastoma multiforme, a deadly form of brain cancer. The treatment stimulates an immune response against the tumor, producing an 'immunogene therapy' effect.
Researchers at Ohio State University discovered that indirubin blocks the migration of glioblastoma cells and endothelial cells, preventing tumor growth and spread. This compound, derived from Indigo plants, may offer a novel therapeutic strategy for treating deadly brain tumors.
Researchers have discovered potential regulatory networks in glioblastoma using microRNAs and transcription factors. The study identified 54 feed-forward loops with functions important to carcinogenesis and unique functions specific to each FFL.
A Phase I clinical trial found that the experimental vaccine ICT-107 targets six antigens found on glioblastoma cells and three on cancer stem cells, improving immune responses and progression-free survival rates in patients. The study also showed that targeting these antigens may be a viable strategy for treating glioblastoma.
A new glioblastoma vaccine has demonstrated safety and effectiveness in a Phase 2 clinical trial, extending median survival to 11 months for patients with recurrent brain cancer. The vaccine was found to induce an immune response against tumor-specific targets, suggesting potential for improved treatment outcomes.
Survival rates for wealthier patients with glioblastoma have improved since 2000, while those in poorer areas and older than 70 have remained stagnant. The addition of temozolomide to post-operative radiation therapy has been shown to improve overall survival in younger patients.
The RTOG 0525 Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma found no significant improvement in overall patient survival or disease progression for patients who received dose-intensive temozolomide plus radiotherapy. However, the trial demonst...
Researchers at IDIBELL found that Nutlin-3a stimulates the p53 pathway, inducing apoptosis and cellular senescence in brain cancer cells. This study suggests MDM2 antagonists may be new therapeutic options for glioblastoma treatment.
A team of University of Cincinnati researchers is sequencing individual glioblastoma genomes and tracking abnormalities in the bloodstream to establish personalized biomarkers. The study aims to guide treatment efforts and identify new therapeutic targets for this aggressive brain tumor.
A personalized dendritic cell vaccine has been shown to increase median survival time in patients with glioblastoma, a deadly form of brain cancer. The vaccine was found to be effective in patients with the mesenchymal subtype of glioblastoma, which accounts for about one-third of all cases.
Glioblastoma cells can transform into blood vessel cells when oxygen is scarce, making treatment efforts less effective. This transformation allows the tumor cells to continue receiving nutrients and oxygen, leading to a resurgence of cancer growth.
A recent study published in the New England Journal of Medicine found that losing the NFKBIA gene promotes glioblastoma multiforme growth and reduces survival. Restoring this gene may improve survival for certain patients with glioblastoma, as it inhibits tumor cell growth and increases sensitivity to chemotherapy.
Researchers at Stanford Medicine have discovered a gene deletion in up to one-fourth of glioblastoma cases, a type of brain cancer with poor survival prospects. The deletion contributes to tumor growth, resistance to therapy, and worsens patient outcomes.
Phase III trial data suggests Tumor Treating Fields (TTF) therapy increases median survival time and improves quality of life scores compared to standard chemotherapy. Younger patients and those with better functional status show an impressive survival advantage.
A new vaccine has been shown to extend survival for patients with glioblastoma, the most deadly form of brain cancer, by eliminating aggressive cancer cells carrying the EGFRvIII marker. The study found that adding the vaccine to standard therapy improved median survival time from 15 months to 26 months.
A team of researchers has discovered genetic changes in glioblastoma, a common type of primary brain cancer, that contribute to its aggressiveness. The study found that tumors with rearrangements in receptor genes are more common than previously thought, suggesting new targets for therapies.
A novel combination therapy of temozolomide and a Notch inhibitor has been shown to be highly effective in reducing tumor growth and recurrence in glioblastoma multiforme. This approach aims to target cancer stem cells, which are resistant to traditional therapies.
Researchers have identified a new cellular communication mechanism in glioblastoma cells, which could be targeted to slow tumor growth. If blocked, this pathway may significantly reduce GBM malignancy.
Researchers at Wake Forest University Baptist Medical Center have identified a way to target and destroy Glioblastoma multiforme (GBM) cells without harming healthy cells. The breakthrough allows for new possibilities in cancer research, potentially leading to less toxic and invasive treatments.